SCHOTT Pharma USA Triples Manufacturing Capacity with $60 Million Pennsylvania Expansion
核心洞察
SCHOTT Pharma USA (搜索) completed a $60 million expansion of its Lebanon County facility that triples the company's manufacturing capacity in the United States and retains more than 200 jobs.
The facility specializes in producing FIOLAX borosilicate glass (搜索) vials for drug containment solutions and delivery systems for injectable drugs, particularly life-saving cancer treatments.
SCHOTT Pharma generated $1.1 billion in global revenue in 2025 and operates two Pennsylvania facilities supporting more than 350 jobs, contributing to the state's $50 billion life sciences industry.
Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger celebrated the completion of SCHOTT Pharma USA (搜索)'s $60 million manufacturing expansion in Lebanon County, marking a significant milestone for Pennsylvania's pharmaceutical manufacturing sector. The expansion triples SCHOTT's manufacturing capacity in the United States while retaining more than 200 jobs at the facility.
Specialized Manufacturing for Cancer Treatments
Since 2003, SCHOTT's Lebanon facility has specialized in drug containment solutions and delivery systems for injectable drugs, producing high-quality core and specialty vials made from FIOLAX borosilicate glass (搜索). These specialized containers are designed to carry and protect life-saving cancer treatments during transit, representing a critical component of the pharmaceutical supply chain.
"From day one, I've worked to grow Pennsylvania's economy and make our Commonwealth the best place to create new jobs and real opportunity," said Governor Shapiro. "Nearly two months ago, I sat down with the President of SCHOTT North America at the NFL Draft in Pittsburgh to talk about why Pennsylvania is the best state in the nation for economic development – and today we are celebrating a significant investment in our Commonwealth."
Strong Financial Performance and Employment Impact
SCHOTT Pharma USA (搜索), the North American branch of Germany's SCHOTT Pharma, focuses on specialty glass, glass-ceramics, and other advanced materials. In 2025, SCHOTT Pharma generated an estimated $1.1 billion in global revenue. The company operates two manufacturing facilities in Pennsylvania – in Lebanon and Duryea – supporting more than 350 jobs across the state.
"SCHOTT Pharma's expansion will boost our innovation economy and further strengthen the pharmaceutical manufacturing ecosystem here in Pennsylvania," said DCED Secretary Rick Siger. "Under Governor Shapiro's leadership, we have an established track record of making the Commonwealth more competitive and a better place to do business."
Pennsylvania's Life Sciences Ecosystem Growth
The SCHOTT expansion represents part of a broader trend of life sciences investment in Pennsylvania. In the last year, major pharmaceutical companies including Johnson & Johnson, Eli Lilly, Eurofins Lancaster Laboratories (搜索), and B. Braun (搜索) announced expansions in Pennsylvania, bringing new jobs and research and development investments to the state.
Pennsylvania's life sciences sector is valued at nearly $50 billion and employs more than 100,000 people across nearly 3,100 companies and research institutions throughout the Commonwealth. Over the past five years, Pennsylvania researchers and companies have secured over 10,700 new life sciences patents, representing the fourth-highest total in the country.
Economic Development and Future Investment
Since taking office, Governor Shapiro has attracted over $41 billion in private-sector investment, creating more than 23,200 jobs across Pennsylvania. The state has received national recognition for its business climate, with Pennsylvania ranking as the only state in the Northeast with a growing economy according to analysis by Moody's Analytics Chief Economist Mark Zandi.
Governor Shapiro's 2026-27 proposed budget includes nearly $100 million for the state's innovation economy through the Innovate in PA 2.0 program, which will provide capital for promising startups, fund clinical trials for life sciences companies, and enhance the Commonwealth's innovation network. The PA First Program, which connects businesses with trained workers and supports job retention and capital investments, will receive an additional $10 million for a total of $38 million in the budget.